Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing-Reference-Cited by-同舟云学术

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing

Published:2017-03 Issue:3 Volume:31 Page:383-395
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Li Ji,Stagg Nicola J.,Johnston Jennifer,Harris Michael J.,Menzies Sam A.,DiCara Danielle,Clark Vanessa,Hristopoulos Maria,Cook Ryan,Slaga Dionysos,Nakamura Rin,McCarty Luke,Sukumaran Siddharth,Luis Elizabeth,Ye Zhengmao,Wu Thomas D.,Sumiyoshi Teiko,Danilenko Dimitry,Lee Genee Y.,Totpal Klara,Ellerman Diego,Hötzel Isidro,James John R.,Junttila Teemu T.

Funder

Wellcome Trust

Royal Society

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference23 articles.

1. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans;Ardlie;Science,2015

2. A novel carcinoembryonic antigen T cell bispecific antibody (Cea Tcb) for the treatment of solid tumors;Bacac;Clin. Cancer Res.,2016

3. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody;Bargou;Science,2008

4. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen;Bluemel;Cancer Immunol. Immunother.,2010

5. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial;Boyd;Leukemia,2012

Cited by 233 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement;Expert Opinion on Biological Therapy;2024-09

3. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies;The Lancet Haematology;2024-09

4. Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy;Molecular Therapy: Oncology;2024-09

5. Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B;Antiviral Research;2024-09